Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
Lancet
    September 2026
  1. GOEL A, Rungta S, Kumar V, Shalimar, et al
    8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.
    Lancet. 2026 Sep 30:S0140-6736(26)01380-2. doi: 10.1016/S0140-6736(26)01380.
    >> Share

    August 2026
  2. SUN HC, Zhu XD, Shen F, Song TQ, et al
    Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.
    Lancet. 2026;408:699-710.
    >> Share

  3. FORNER A
    TALENTOP study: a new era for conversion surgery in advanced hepatocellular carcinoma?
    Lancet. 2026;408:668-669.
    >> Share

    April 2026
  4. GRAUPERA I, Thiele M, Castera L, Pera G, et al
    Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.
    Lancet. 2026;407:1448-1458.
    >> Share

  5. LIANG F, Zhou S, Wang Z, Fan J, et al
    Perioperative immunotherapy for resectable hepatocellular carcinoma - Authors' reply.
    Lancet. 2026;407:1334.
    >> Share

  6. LI Z, Tang Y
    Perioperative immunotherapy for resectable hepatocellular carcinoma.
    Lancet. 2026;407:1332.
    >> Share

  7. JIN W, Xue M, Luo S
    Perioperative immunotherapy for resectable hepatocellular carcinoma.
    Lancet. 2026;407:1332-1334.
    >> Share

    March 2026
  8. VON SETH E, Karlsen TH, Tanaka A, Ponsioen C, et al
    Primary sclerosing cholangitis.
    Lancet. 2026 Mar 20:S0140-6736(25)02582-6. doi: 10.1016/S0140-6736(25)02582.
    >> Share

    February 2026
  9. VALENTI L, Periti G
    Once-monthly efimosfermin for non-cirrhotic MASH.
    Lancet. 2026 Feb 5:S0140-6736(25)02431-6. doi: 10.1016/S0140-6736(25)02431.
    >> Share

  10. NOUREDDIN M, Kowdley KV, Odrljin T, Bain G, et al
    Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2026 Feb 5:S0140-6736(25)02276-7. doi: 10.1016/S0140-6736(25)02276.
    >> Share

    December 2025
  11. SCHOENFELD JD, Haas-Kogan DA, O'Neill AF
    Abscopal response in a patient with fibrolamellar hepatocellular carcinoma following radiotherapy.
    Lancet. 2025;404:2603-2604.
    >> Share

    November 2025
  12. GALLE PR, Yau T, Decaens T
    Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW - Authors' reply.
    Lancet. 2025;406:2423-2424.
    >> Share

  13. SHI R, Li J, Zhang L
    Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW.
    Lancet. 2025;406:2422-2423.
    >> Share

  14. SANTHOSH A, Sreenath ND
    Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW.
    Lancet. 2025;406:2421-2422.
    >> Share

  15. NOUREDDIN M, Harrison SA, Loomba R, Alkhouri N, et al
    Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
    Lancet. 2025 Nov 11:S0140-6736(25)02114-2. doi: 10.1016/S0140-6736(25)02114.
    >> Share

    October 2025
  16. WANG Z, Fan J, Zhou S, Sun Y, et al
    Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
    Lancet. 2025 Oct 19:S0140-6736(25)01720-9. doi: 10.1016/S0140-6736(25)01720.
    >> Share

  17. KASEB A, Pawlik TM
    Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma.
    Lancet. 2025 Oct 19:S0140-6736(25)02104-X. doi: 10.1016/S0140-6736(25)02104.
    >> Share

    August 2025
  18. LOOMBA R, Morgan E, Yousefi K, Li D, et al
    Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2025;406:821-831.
    >> Share

  19. NOUREDDIN M, Frias JP, Neff GW, Lucas KJ, et al
    Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
    Lancet. 2025;406:719-730.
    >> Share

  20. KUDO M, Ren Z, Finn RS, Llovet JM, et al
    Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial - Authors' reply.
    Lancet. 2025;406:694.
    >> Share

  21. ONDER AH
    Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial.
    Lancet. 2025;406:693.
    >> Share

  22. SHERRY AD, Dudzinski SO, Ludmir EB
    Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial.
    Lancet. 2025;406:693-694.
    >> Share

    July 2025
  23. CHAN SL, Sun HC, Xu Y, Zeng H, et al
    The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment.
    Lancet. 2025 Jul 25:S0140-6736(25)01042-6. doi: 10.1016/S0140-6736(25)01042.
    >> Share

    May 2025
  24. VITHAYATHIL M, Sharma R
    Nivolumab plus ipilimumab in hepatocellular carcinoma.
    Lancet. 2025 May 7:S0140-6736(25)00417-9. doi: 10.1016/S0140-6736(25)00417.
    >> Share

  25. YAU T, Galle PR, Decaens T, Sangro B, et al
    Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.
    Lancet. 2025 May 7:S0140-6736(25)00403-9. doi: 10.1016/S0140-6736(25)00403.
    >> Share

    February 2025
  26. RAHIM MN, Williamson C, Kametas NA, Heneghan MA, et al
    Pregnancy and the liver.
    Lancet. 2025;405:498-513.
    >> Share

    January 2025
  27. REITER FP, Geier A
    TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma.
    Lancet. 2025 Jan 8:S0140-6736(24)02680-1. doi: 10.1016/S0140-6736(24)02680.
    >> Share

  28. SANGRO B, Kudo M, Erinjeri JP, Qin S, et al
    Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet. 2025 Jan 8:S0140-6736(24)02551-0. doi: 10.1016/S0140-6736(24)02551.
    >> Share

  29. KUDO M, Ren Z, Guo Y, Han G, et al
    Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
    Lancet. 2025 Jan 8:S0140-6736(24)02575-3. doi: 10.1016/S0140-6736(24)02575.
    >> Share

    November 2024
  30. ISRAELSEN M, Francque S, Tsochatzis EA, Krag A, et al
    Steatotic liver disease.
    Lancet. 2024;404:1761-1778.
    >> Share

    October 2024
  31. PONVILAWAN B, Roth MT
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1405.
    >> Share

  32. QIN S
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial - Author's reply.
    Lancet. 2024;404:1405-1406.
    >> Share

  33. WANG JK, Liao R
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1404-1405.
    >> Share

  34. LI H, Yan J, Han T
    Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
    Lancet. 2024;404:1403-1404.
    >> Share

    September 2024
  35. ADAM R, Piedvache C, Chiche L, Adam JP, et al
    Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial.
    Lancet. 2024;404:1107-1118.
    >> Share

  36. HEINEMANN V, Stintzing S
    Liver transplantation in metastatic colorectal cancer: a new standard of care?
    Lancet. 2024;404:1078-1079.
    >> Share

  37. TANAKA A, Ma X, Takahashi A, Vierling JM, et al
    Primary biliary cholangitis.
    Lancet. 2024;404:1053-1066.
    >> Share

    August 2024
  38. MAIWALL R, Kulkarni AV, Arab JP, Piano S, et al
    Acute liver failure.
    Lancet. 2024;404:789-802.
    >> Share

  39. CHOW PKH, Hack SP, Spahn JH, Yopp AC, et al
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial - Authors' reply.
    Lancet. 2024;404:657-658.
    >> Share

  40. ROSE S, Ashraf MU, Premkumar M
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:656-657.
    >> Share

  41. CHEN Z, Lan X, Du C, Xiao H, et al
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:656.
    >> Share

  42. DONADON M, Di Martino M, Rigamonti C
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:655-656.
    >> Share

  43. SHIN H, Lee JH
    Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Lancet. 2024;404:654-655.
    >> Share

    June 2024
  44. ENG C, Yoshino T, Ruiz-Garcia E, Mostafa N, et al
    Colorectal cancer.
    Lancet. 2024 Jun 20:S0140-6736(24)00360-X. doi: 10.1016/S0140-6736(24)00360.
    >> Share

    May 2024
  45. DE OLIVEIRA FRANCO A, Uberti Dos Santos V, von Ameln Lovison O, Zavascki AP, et al
    Invasive liver abscess syndrome with central nervous system involvement caused by hypermucoviscous Klebsiella pneumoniae: positive string test.
    Lancet. 2024;403:2257-2258.
    >> Share

    April 2024
  46. KARLSEN TH, Rutter H, Carrieri P, Zelber-Sagi S, et al
    The EASL-Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality.
    Lancet. 2024;403:1522-1524.
    >> Share

    November 2023
  47. VON KODOLITSCH Y, Kubisch C, Carrel T
    AATD as a genetic risk factor for aneurysmal disease - Authors' reply.
    Lancet. 2023;402:1626.
    >> Share

  48. KUEPPERS F
    AATD as a genetic risk factor for aneurysmal disease.
    Lancet. 2023;402:1625-1626.
    >> Share

    October 2023
  49. VOGEL A, Meyer T, Saborowski A
    IMbrave050: the first step towards adjuvant therapy in hepatocellular carcinoma.
    Lancet. 2023 Oct 23:S0140-6736(23)01962-1. doi: 10.1016/S0140-6736(23)01962.
    >> Share

  50. QIN S, Chen M, Cheng AL, Kaseb AO, et al
    Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Oct 20:S0140-6736(23)01796-8. doi: 10.1016/S0140-6736(23)01796.
    >> Share

    September 2023
  51. PINATO DJ, D'Alessio A, Celsa C, Manfredi GF, et al
    The price and value of therapeutic synergy in liver cancer.
    Lancet. 2023;402:1108-1110.
    >> Share

  52. TAPPER EB, Serper M
    Screening for advanced liver disease in the general population.
    Lancet. 2023;402:941-943.
    >> Share

  53. SERRA-BURRIEL M, Juanola A, Serra-Burriel F, Thiele M, et al
    Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.
    Lancet. 2023;402:988-996.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016